Oncology Research International Limited (ORIL) is an Australian, public, unlisted company.
The registered office (ACN: 067 964 621) of the Company is in Perth, WA, and the scientific program is driven and managed from Adelaide, SA.
The founder and current director Dr Michael Wayte was diagnosed with bowel cancer in 1986. After following a demanding and restrictive vegetarian diet with specific plant-based therapies, he recovered and is alive and well today. As a result of his recovery he founded ORIL with the objective of researching plant-based therapies for cancer.
ORIL utilizes an outsourcing approach to development, tailored to its specific needs at any stage of the R&D program. This is a cost-effective approach which maximises the use of existing internal skills and purchases external services on a fee for service basis.
ORIL’s CEO oversees a network of outsourced organizations which includes medical research institutes, universities, hospitals and specialist contract research organizations. Where possible, and provided the organization has the expertise for the particular project, the R&D is conducted in Australia.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia